Hydralazine Injection Rx
Generic Name and Formulations:
Hydralazine (as HCl) 20mg/mL; IM or IV inj; contains parabens.
Various generic manufacturers
Indications for Hydralazine Injection:
Severe essential hypertension when oral therapy not feasible or there is an urgent need to lower blood pressure.
Monitor BP closely. 20–40mg; repeat as needed. Advanced renal damage: reduce dose.
Not recommended; doses of 1.7–3.5mg/kg per day in 4–6 divided doses have been used.
Coronary artery disease. Mitral valve disease.
Suspected coronary artery disease. Cerebrovascular accidents. Aortic aneurysm. Increased intracranial pressure. Renal disease. Treat paresthesias and/or numbness with pyridoxine. Discontinue if blood dyscrasias occur. Obtain CBC and ANA titer periodically; consider discontinuing if SLE occurs. Surgery. Pregnancy (Cat.C). Nursing mothers.
Caution with MAOIs. Profound hypotension with potent parenteral antihypertensives (eg, diazoxide). Antagonized by NSAIDs. May block epinephrine.
Headache, anorexia, GI disturbances, palpitations, edema, flushing, nasal congestion, lacrimation, rash, tachycardia, angina, orthostatic hypotension, blood dyscrasias, peripheral neuritis, SLE.
Formerly known under the brand names Apresoline (inj, tabs); Dralzine (tabs).
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Immune Checkpoint Inhibitors for NSCLC: Current and Future Approaches
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Erdafitinib Granted FDA Breakthrough Therapy Designation for Urothelial Carcinoma
- NSCLC: Stratifying Patients With Complex EGFR Mutations
- Confronting Racial Disparities in Prostate Cancer Survival Outcomes
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- NSCLC: Pretreatment Weight Loss May Be Linked to Socioeconomic Status
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC